Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

PURPOSE: We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. M...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean Charles, Wen, Patrick Y., Zielinski, Christoph, Cabanillas, Maria E., Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima, Keam, Bhumsuk
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2018
Teme:
RAPID COMMUNICATION
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791845/
https://ncbi.nlm.nih.gov/pubmed/29072975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.6785
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items